MKMatasaburo Kobayashi

Matasaburo Kobayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matasaburo Kobayashi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    123I−FP−CIT uptake and behavioral disinhibition in the frontotemporal dementia spectrum: an exploratory DAT−SPECT study

    by Shigeki Katakami, Yuto Satake, Daiki Taomoto, Yuhei Okura, Matasaburo Kobayashi, Kayo Takeda, Fuyuki Koizumi, Takashi Suehiro, Kohji Mori, Manabu Ikeda, et al.

    Behavioral disinhibition is a core feature of behavioral variant frontotemporal dementia (bvFTD) and occurs across related FTD-spectrum presentations. Serotonergic dysfunction may contribute to behavioral dysregulation; therefore, we primarily examined dorsal raphe (DR)-centered midbrain ¹²³I-FP-CIT uptake as an indirect extrastriatal signal that may partly reflect serotonin transporter-related binding. Because striatal dopaminergic circuits support reward learning, behavioral inhibition, and context-dependent behavioral updating, striatal uptake was examined exploratorily. This retrospective exploratory study included 21 patients within the FTD spectrum who underwent Neuropsychiatric Inventory (NPI) assessment, magnetic resonance imaging, and ¹²³I-FP-CIT single-photon emission computed tomography within a 3-month window. The primary outcome was the NPI disinhibition score. DR-centered midbrain and striatal specific uptake ratios (SURs) were calculated using the cerebellum as the reference region. Age- and sex-adjusted quasi-Poisson models with a log link were fitted. DR-centered midbrain SUR was not significantly associated with disinhibition in the primary model (β = −1.027, p = 0.353). In the exploratory model, higher striatal SUR was nominally associated with lower disinhibition scores (β = −0.438, p = 0.022). The negative direction of the striatal association was generally preserved across sensitivity analyses, although nominal significance was not retained in all models. DR-centered midbrain SUR was not significantly associated with behavioral disinhibition in this small FTD-spectrum cohort. Lower striatal SUR showed a directionally consistent but sensitivity-dependent nominal association with greater disinhibition. This hypothesis-generating finding may reflect broader frontostriatal disease burden, striatal neurodegeneration, parkinsonian-spectrum overlap, or partial-volume effects and does not establish a disinhibition-specific dopaminergic mechanism.

  • Open Access

    Progression to Dementia in Very Late‐Onset Schizophrenia‐Like Psychosis Stratified by A lzheimer's Disease and L ewy Body Disease Biomarkers: A Retrospective Cohort Study

    by Yuto Satake, Hideki Kanemoto, Daiki Taomoto, Kayo Takeda, Shigeki Katakami, Matasaburo Kobayashi, Keiko Matsunaga, Kayako Isohashi, Takashi Suehiro, Kenji Yoshiyama, et al.

    Background: Very late‐onset schizophrenia‐like psychosis (VLOSLP) is clinically heterogeneous, and its relationship with dementia‐related neurodegenerative disease remains unresolved. We examined whether Alzheimer's disease (AD) and Lewy body disease (LBD) biomarker status were associated with dementia progression in VLOSLP. Methods: We retrospectively identified patients who visited the University of Osaka Hospital between January 2018 and December 2023 and met criteria for VLOSLP. Twenty‐two participants with AD and/or LBD biomarker data and at least one follow‐up assessment within 775 days were classified as biomarker‐negative (BMs‐neg; n = 7) or biomarker‐positive (BMs‐pos; n = 15). Group comparisons were performed using Mann–Whitney U tests and Fisher's exact tests. Results: The BMs‐pos group showed older onset age and lower memory scores than the BMs‐neg group. Dementia progression was more frequent in the BMs‐pos group than in the BMs‐neg group, although the difference was not statistically significant (8/15 [53.3%] vs. 1/7 [14.3%]; p = 0.165; odds ratio 6.31; 95% CI 0.55–353.18). Five of eight participants with AD biomarker positivity progressed to AD dementia. Three of seven participants with LBD biomarker positivity progressed to dementia, including two diagnosed with dementia with Lewy bodies. Follow‐up MMSE, CDR, and CDR‐SB scores differed significantly between groups. Conclusions: AD and/or LBD biomarker‐positive VLOSLP may be associated with greater dementia progression and cognitive decline, although findings should be interpreted cautiously given the small sample size and retrospective design. These results support the clinical value of considering neurodegenerative biomarkers when evaluating the prognosis and underlying pathology of VLOSLP.


  • Efficacy, safety and predictors of response to electroconvulsive therapy in Lewy body disease

    by Matasaburo Kobayashi, Yoshiyuki Nishio, Yuto Satake, Hideki Kanemoto, Tomotaka Ishida, Yoshiyasu Kigawa, Shigeki Hatakeyama, Kumiko Utsumi, Manabu Ikeda


  • Open Access

    Efficacy, safety and predictors of response to electroconvulsive therapy in Lewy body disease

    by Matasaburo Kobayashi, Yoshiyuki Nishio, Yuto Satake, Hideki Kanemoto, Tomotaka Ishida, Yoshiyasu Kigawa, Shigeki Hatakeyama, Kumiko Utsumi, Manabu Ikeda

    Background and objectivesSevere, treatment-resistant psychiatric symptoms are common in Lewy body disease (LBD). As pharmacotherapy is often limited by poor efficacy and adverse effects, alternative treatments are needed. While electroconvulsive therapy (ECT) has shown promise, systematic data on its use in LBD remain scarce. This study aimed to evaluate the efficacy and safety of ECT in LBD and identify predictors of a favorable response.MethodsWe compared 40 patients with LBD with 33 with schizophrenia and 24 with affective disorders who received ECT between 2012 and 2023. The primary outcome was short-term efficacy, measured using the Clinical Global Impressions-Improvement (CGI-I) scale. Long-term outcomes were assessed by 6-month and 2-year readmission rates. Ordinal logistic regression was used to identify clinical predictors of response in the LBD group.ResultsShort-term efficacy in LBD was comparable to schizophrenia but lower than in affective disorders (median CGI-I: 2 vs. 1, p < 0.05). In LBD, psychosis and catatonia predicted a favorable response (p = 0.044). While 6-month readmission rates were similar across groups, the 2-year rate was highest in LBD (61.5%). ECT was well-tolerated, with no serious adverse events; transient amnesia was the most common side effect.ConclusionECT is an effective and safe treatment for severe psychiatric symptoms in LBD, particularly in patients with psychosis or catatonia. Although its short-term efficacy may be less pronounced than in affective disorders, it represents a valuable therapeutic alternative when pharmacotherapy is challenging. Further research is warranted to confirm long-term benefits and optimize patient selection.